PlaqueTec, a Cambridge, UK-based company identifying endotype-specific biomarkers to advance precision medicine for coronary artery disease (CAD), raised £6.4M in funding.
The round was led by Lord Moynihan of Chelsea alongside the Future Fund, with support from existing investors.
The company intends to use the funds to support its ongoing Biopattern trial, designed to improve understanding of CAD pathobiology and how it varies between individuals, and to build Biocarta®, its novel biomarker discovery tool.
Led by Martin Stapleton, Chairman, PlaqueTec is involved in identifying endotype-specific biomarkers to advance precision medicine for coronary artery disease (CAD). CAD, where atherosclerotic plaque build-up narrows or blocks the arteries that supply blood to the heart, is a leading cause of death globally. To address this, the company has developed a proprietary technology and data analysis platform to endotype patients and uncover potential biomarkers of coronary vascular function and plaque progression.
BIOCARTA is a bioinformatics discovery platform that interrogates data and groups patients with CAD into endotypes with defined signatures of the disease. It correlates in vivo biomarkers localising at the disease site with plaque imaging, genomic analysis, blood biochemistry and clinical and demographic phenotypes to further enhance a unique understanding of disease. PlaqueTec is using BIOCARTA to identify biomarkers to accurately assess patients and therefore inform more targeted therapeutic interventions, transforming patient care.
At the heart of BIOCARTA is PlaqueTec’s BIOPATTERN trial, which uses its proprietary blood sampling device, the Liquid Biopsy System™, to collect samples containing biomolecules localising at or being released by coronary plaque.
FinSMEs